Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


R2 v. ISSI

This article was originally published in The Gray Sheet

Executive Summary

Intellectual property suit charges Intelligent Systems Software, Inc. with infringing three patents covering the ways in which R2 devices scan, process and display images. PMA-approved by FDA in 1998 for use with film-based screening mammography to assist radiologists in minimizing false readings, R2's ImageChecker received an expanded indication for diagnostic mammograms in 2001. In April, the agency approved R2 CAD technology for use with the GE Senographe full-field digital mammography system. ISSI's MammoReader was PMA-approved for "identifying areas on the original mammogram that may warrant a second review" in January, preceding film digitizer Howtek's acquisition of the firm in February (1"The Gray Sheet" Feb. 25, 2002, p. 8)...

You may also be interested in...

Howtek MammoReader Acquisition Has Value Approaching $30 Mil.

Film digitizer Howtek, Inc. is entering the mammography computer-aided detection market through the acquisition of MammoReader developer Intelligent Systems Software, Inc

UK Grants First Worldwide Authorization For PfIzer/BioNTech COVID-19 Vaccine

Wockhardt Preps To Deliver 100M Doses Of AZ Vaccine

As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts